Immutep announces it has received a EUR 1,595,475 research and development tax incentive payment in cash from the French Government under its Credit d’Impot Recherche scheme, CIR. The “Credit d’Impot Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure. Immutep qualifies for the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible R&D activities conducted in the European Union in the 2022 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government’s R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia. As previously announced, in October 2023, the company received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program for the eligible R&D activities conducted in financial year 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMMP:
- Immutep Receives A$2.6 million R&D Tax Incentive from French Government
- Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
- Immutep announces site expansion for INSIGHT-003 Phase I trial
- Immutep completes enrollment in TACTI-003 Phase IIb trial
- Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Questions or Comments about the article? Write to editor@tipranks.com